AVITA Medical (NASDAQ:RCEL – Get Free Report) and RenovaCare (OTCMKTS:RCAR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.
Profitability
This table compares AVITA Medical and RenovaCare’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
AVITA Medical | -88.41% | -84.07% | -47.63% |
RenovaCare | N/A | N/A | N/A |
Institutional and Insider Ownership
27.7% of AVITA Medical shares are held by institutional investors. 1.8% of AVITA Medical shares are held by company insiders. Comparatively, 0.9% of RenovaCare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
AVITA Medical | $54.14 million | 4.45 | -$35.38 million | ($1.76) | -5.31 |
RenovaCare | N/A | N/A | -$4.47 million | N/A | N/A |
RenovaCare has lower revenue, but higher earnings than AVITA Medical.
Risk and Volatility
AVITA Medical has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, RenovaCare has a beta of -99.34, meaning that its share price is 10,034% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for AVITA Medical and RenovaCare, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
AVITA Medical | 0 | 2 | 1 | 0 | 2.33 |
RenovaCare | 0 | 0 | 0 | 0 | N/A |
AVITA Medical currently has a consensus target price of $15.00, indicating a potential upside of 60.60%.
Summary
AVITA Medical beats RenovaCare on 5 of the 9 factors compared between the two stocks.
About AVITA Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
About RenovaCare
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.